100 Prevelance of Cancer by Type

Cancer prevalence by type based on new cases in U.S. in 2023

The purpose of this table is to have an appreciation of the relative rate of occurrence by cancer type.

Cancer Type % of Cases (2023) Major Variants Variant Prevalence
Breast 15.2% Invasive Ductal Carcinoma 70-80% of all breast cancers
Invasive Lobular Carcinoma 10-15% of all breast cancers
Triple-negative 10-15% of all breast cancers
HER2-positive 15-20% of all breast cancers
Prostate 13.7% Adenocarcinoma ~95% of prostate cancers
Lung 12.2% Non-Small Cell Lung Cancer (NSCLC) ~85% of all lung cancers
Small Cell Lung Cancer (SCLC) ~10-15% of all lung cancers
Colorectal 7.8% Colon Cancer ~65% of colorectal cancers
Rectal Cancer ~35% of colorectal cancers
Bladder 4.2% Urothelial Carcinoma ~90% of bladder cancers
Non-Hodgkin Lymphoma 4.1% Diffuse Large B-Cell Lymphoma (DLBCL) ~30-40% of non-Hodgkin lymphomas
Follicular Lymphoma ~20% of non-Hodgkin lymphomas
Pancreatic 3.3% Adenocarcinoma Majority of pancreatic cancers
Thyroid 2.2% Papillary Thyroid Carcinoma ~80-85% of thyroid cancers
Follicular Thyroid Carcinoma ~10-15% of thyroid cancers
Stomach 1.4% Adenocarcinoma Majority of stomach cancers
Liver 2.1% Hepatocellular Carcinoma (HCC) ~75% of liver cancers
Cholangiocarcinoma ~10-15% of liver cancers
Brain and CNS 1.3% Glioblastoma Multiforme ~50% of malignant brain tumors
Other Cancers 14.6% Various Remaining cases not classified above

Notes: